Key result
Redo composite valve graft replacement for failed composite grafts resulted in a hospital mortality of 14.3% and a 3-year survival rate of 85.7%.
Cohort (n=14)
Redo composite valve graft replacement can be performed with acceptable hospital mortality (14.3%) and good 3-year survival (85.7%) despite high baseline surgical risk.
Describes feasible redo composite graft technique in small series; leaves open need for larger validation studies.
BACKGROUND AND AIM OF THE STUDY: The replacement of a failed composite valve graft is technically more demanding and is associated with increased morbidity and mortality. We present our technique and outcomes for reoperations for composite graft failures. METHODS: Between September 2011 and June 2017, 14 patients underwent a redo composite graft replacement. Twelve patients (85.7%) were male, and mean age was 58.4 years ± 12 standard deviation (SD). One patient had two previous root replacements. Indications for reoperation were endocarditis (8), aortic pseudoaneurysm (3), and aortic prosthesis thrombosis (3). Mean logistic EuroSCORE and EuroSCORE II were 30.8% and 14.7%, respectively. RESULTS: A mechanical composite graft was used in 12 patients and biological composite grafts were used in two patients. Hospital mortality was 14.3% (n = 2). One patient (7.1%) required reoperation for bleeding, One patient (7.1%) had mechanical ventilation >24 h, and four patients (28.6%) required implantation of a permanent pacemaker. Median intensive care unit and hospital stays were 3 days (interquartile range [IQR] 1-5) and 10 days (IQR 6.5-38.5). One patient experienced recurrent prosthetic valve endocarditis 14 months after operation. On follow-up, 11 of 12 survivors were in New York Heart Association class I or II. Survival at 3 years was 85.7% ± 9.4% SD. CONCLUSIONS: Composite valve graft replacement can be performed with acceptable morbidity and mortality with good mid-term survival.
No takes yet. Share an insight, caveat, or question.
Maroto et al. (2018) conducted a cohort in Composite valve graft failure (n=14). Redo composite graft replacement was evaluated on Hospital mortality. Redo composite valve graft replacement for failed composite grafts resulted in a hospital mortality of 14.3% and a 3-year survival rate of 85.7%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: